Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Kswdeluxon Apr 27, 2022 6:47pm
378 Views
Post# 34637226

Updated corporate presentation dated April 2022

Updated corporate presentation dated April 2022 I just got around to looking at the latest Corporate Presentation dated April 2022.  Yeah, a lttle slow this time...

Page 13 shows AWARE-1 Biomarker Data Reported Q4 2021 

That seemed to be the end of that, but I just noticed in the updated corporate presentation under milestones page 30, I think they have added 

         AWARE-1 beast cancer study: biomarker data

and a TIMING date of Q2 2022. I do not recall seeing this milestone in the previous corporate presentation.


I wonder if this will be more of the same old - same old - regurgitated data, SAFE and WELL-TOLERATED, and MAY BE a predictive biomarker that is driving our rediculously high soring share prices, or if ONC will actually be able to release something of significance that might boost SP and save my warrants from burning up in a firey ball of fury on June 1st.

It would have to be very significant NEW data to save the warrants... otherwise June 1st will be a sad day I feel.

Yes, took a gamble on a bunch of warrants... seems it was just that... with less than 5 weeks to go :(

Would be nice for something to happen before June 1st, or even an extension on the warrants.
But based on SP, the market has absolutely no faith in anything of significance happing until late Q4 2022.  
At least not in the near future.

Nothing of significance ever seems to happen in the market these days without some leaked news resulting in some increase in volume and increase in SP, but we are seeing nothing, significantly low volumes, watching the SP drop every day. So, it would seem there is nothing in the wind.  Hmmm...

I am still hopeful, but no sense selling warrants now for a 93.54% loss when I can be a real winner at 100% loss... lol

:(
<< Previous
Bullboard Posts
Next >>